Cases & Deals

Ventac invests in multimmune

Clients Ventac Partners GmbH

Jones Day counseled Ventac Partners GmbH in connection with its purchase of Common Stock in a private placement by multimmune GmbH, a private biopharmaceutical company focused on the development of innovative therapeutic approaches for the treatment of cancers.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.